Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FLU-028
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
FLU-028 refers to a Phase II clinical trial (NCT07204964) evaluating GSK's investigational mRNA-based multivalent seasonal influenza vaccine candidates, specifically GSK4382276 (also known as FLUm3HA.b-3NA) and FLUm3HA-3NA. Developed by GSK in collaboration with CureVac, these next-generation vaccines are designed to target both hemagglutinin (HA) and neuraminidase (NA) antigens of influenza A and B strains. This dual-antigen approach aims to provide broader protection, reduce disease severity, and limit viral transmission compared to traditional HA-only vaccines. Following positive Phase II results from the Flu-028 trial, which demonstrated superior immunogenicity compared to licensed standard- and high-dose inactivated comparators, GSK selected the optimized B-strain HA candidate, GSK4382276, to advance into Phase III clinical development.
- Other names
- FLUm3HA-3NAFLUm-3HA-3NAFLUm 3HA-3NAFLUm3HA.b-3NAFLUm-3HA.b-3NAFLUm 3HA.b-3NA
Beyond the preview
Go deeper on FLU-028.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FLU-028.